Drug-resistant tuberculosis among foreign-born persons in Italy

To the Editors:

Over the last few years, drug-resistant tuberculosis (TB) has emerged as an important threat to public health in industrialised countries. In Italy, the most recent data on resistance to the first-line drugs (FLDs) streptomycin (S), isoniazid (H), rifampicin (R) and ethambutol (E) were reported for the period 1998–2001 [1]. These studies determined the prevalence of resistance among new cases and previously treated cases, but no information was available on the contribution of immigration, which plays an important role on TB epidemiology in low-incidence countries [2].

In the last decade, while the notified incidence of TB in Italy was stable at approximately seven cases per 100,000 people annually, the proportion of foreign-born persons (FBPs) with TB increased from 22% in 1999 to 46% in 2008 [3]. In the same period, the proportion of African-born persons with TB decreased from 51% to 30%, whereas the proportion of European cases increased from 16% to 33%, most of them being born in Eastern Europe, including Former Soviet Union (FSU) countries.

Eastern European countries are among those with the highest TB rates caused by multidrug-resistant (MDR) Mycobacterium tuberculosis strains (i.e. resistant to at least H and R) and extensively drug-resistant (XDR) strains (i.e. MDR strains resistant to any fluoroquinolone and to at least one injectable second-line drug (SLD): kanamycin (KM), capreomycin (CM), amikacin (AK)) [4].

Reliable drug susceptibility testing (DST) is essential to diagnose TB caused by drug-resistant strains. In Italy, a network of laboratories coordinated by the World Health Organization (WHO) Supranational Reference Laboratory (SRL) in Rome performs drug susceptibility proficiency testing for S, H, R, E (five rounds from 1997 to 2010) and SLD (KM, AK, CM, OFL, moxifloxacin (MX), ethionamide (ETH), linezolid (LZ) was determined by the MGIT system, using the following concentrations: 1.0, 0.1, 1.0, 5.0, 5.0, 1.0, 2.5, 2.0, 0.25, 5.0 and 1.0 μg·mL⁻¹, respectively [5, 6].

Data on resistance to FLDs and SLDs of strains isolated in 2008–2010 from IBPs and FBPs are given in table 1. The five countries mainly contributing to the FBP group were Romania (28.7%), Morocco (9.9%), Peru (5.8%), Pakistan (5.8%) and India (5.6%). A lower FBP proportion emigrated from high MDR-TB burden FSU countries [4], including Ukraine (2.5%), Moldova (2.2%) and others (Russia, Georgia, Latvia, Armenia and Belarus (<1%)). We stratified FBP data in three groups: Romania (the largest TB group), FSU (the highest MDR-TB prevalence group) and all others.

Out of 5,267 TB cases with known country of birth (table 1), FBPs were significantly younger than IBPs (mean ± SD 35 ± 14 versus 58 ± 22 yrs, respectively; p < 0.0001) and arrived in Italy from 84 countries. 40% came from Europe (29% from Romania, 6% from FSU countries and 5% from other European countries), 27% from Africa, 21% from Asia and 12% from the Americas. 61% of IBPs and 63% of FBPs were male (p = 0.14). 81% of IBPs and 78% of FBPs were new cases (p-value: 0.007). Noticeably, cases from the FSU were more likely to harbour strains resistant to one or more FLDs (47.6%) than those isolated from IBPs, Romanian-born persons and other FBPs (27.0% (p < 0.0001), 29.8% (p < 0.0001) and 35.3% (p = 0.003), respectively).

Overall, the highest prevalence of monoresistance was seen for S and H, while monoresistance to R and E was low (<1%). Monoresistance to H in patients from the FSU (6.9%) was significantly higher than in IBPs (3.2%) (p = 0.02). The prevalence of any form of resistance to S and H was higher than those to R and E.

The overall MDR-TB prevalence was 3.8%, with large differences between groups. The MDR rate was low in IBPs different TB-specific settings. In 2010, SMIRA covered 59% of nationwide notified cases, allowing preparation of the national annual report on drug resistance [3].

TB cases with positive M. tuberculosis cultures were routinely examined by SMIRA laboratories for susceptibility to S, H, R and E. DST procedures included testing on solid media (proportion method in Löwenstein–Jensen (LJ) medium) and liquid media (BACTEC 460 TB (BACTEC) and MGIT 960 (MGIT) systems; Becton Dickinson, Sparks, MD, USA). In 2008, the LJ, BACTEC and MGIT procedures were used by 14%, 10% and 76% of laboratories, respectively. In 2009, the use of MGIT increased, and reached 100% in 2010. MDR-TB isolates were sent to the SRL to retest susceptibility to FLDs and test susceptibility to SLDs. Susceptibility to S, H, R, E, KM, AK, CM, OFL, moxifloxacin (MX), ethionamide (ETH), linezolid (LZ) was determined by the MGIT system, using the following concentrations: 1.0, 0.1, 1.0, 5.0, 5.0, 1.0, 2.5, 2.0, 0.25, 5.0 and 1.0 μg·mL⁻¹, respectively [5, 6].

Reliable drug susceptibility testing (DST) is essential to diagnose TB caused by drug-resistant strains. In Italy, a network of laboratories coordinated by the World Health Organization (WHO) Supranational Reference Laboratory (SRL) in Rome performs drug susceptibility proficiency testing for S, H, R, E (five rounds from 1997 to 2010) and SLD (KM, AK, CM and ofloxacin (OFL)) (one round in 2010) [5].

In order to understand the impact of immigration on drug-resistant TB in Italy, we conducted a retrospective study over the period 2008–2010 to investigate drug-resistance proportions and drug-resistance profiles of M. tuberculosis strains circulating among FBPs and Italian-born persons (IBPs).

Our laboratory network (Italian Multicentre Study on Resistance to Antituberculosis drugs (SMIRA)) is composed of 30 hospital mycobacteriology laboratories located in 19 out of 20 Italian regions, selected on the basis of: 1) technical skills for DST, periodically evaluated by proficiency testing [5]; 2) number of first-line DSTs performed annually (a mean of 72, 88 and 78 DSTs per laboratory in 2008, 2009 and 2010, respectively); and 3) convenient geographic location reflecting...
cases (175 out of 198) were resistant to at least three FLDs. The highest frequency of the SHRE resistance pattern was seen in strains collected from patients coming from FSU (20.7%) and the lowest in strains collected from IBPs (0.5%) (p < 0.0001).

Among 80 MDR strains tested for susceptibility to SLDs (68 from FBPs and 12 from IBPs), the highest total percentage of resistance was seen to ETH (47.5%), followed by KM, AK and CM (≥20%). Overall, the drugs potentially active for clinical use were OFL, MX and LZ (18.8%, 16.2% and 12.5% resistance, respectively). Six MDR-TB isolates were XDR strains (two from Ukraine, and one each from Moldova, Romania, Peru and
Bangladesh), with LZ being the only drug active against all of them.

Few nationwide data have been reported on FLD and SLD resistance in FBPs [7]. In Italy, the MDR-TB prevalence in FBPs was consistent with that of their native countries (e.g. in 2009: Romania, 11.2%; Ukraine, 19%; Moldova, 44.3%) [4, 8]. The study results demonstrated, for the first time under a national perspective, that: 1) IBP contribution to MDR-TB is low; and 2) MDR-TB strains isolated from FBPs (particularly from the FSU) are highly resistant to FLDs. Thus, efficient strategies for rapid identification and treatment of MDR-TB cases in FBPs are imperative. SLD data showed that resistance to LZ seemed to be still low, suggesting its use for difficult-to-treat cases. Indeed, LZ-containing combinations are administered for off-label therapy of MDR/XDR-TB in Italy and other countries [9, 10]. However, new drugs are necessary to treat these life-threatening cases.

Acknowledgments: The members of the SMIRA Group were: C. Piersimoni (Ospedali Riuniti, Ancona, Italy); P. Lorenzetti (Ospedale di Acosta, Aosta, Italy); D. Costa (Policlinico di Bari, Bari, Italy); A. Grimaldi (Ospedale Fallacara, Triggiano, Bari); M. Aroso and A. Goglio (Ospedali Riuniti, Bergamo, Italy); C. Mazza and L. Squintani (Ospedale Maggiore, Bologna, Italy); C. Larcher and E. Fizzera (Azienda Sanitaria dell’Alto Adige, Bolzano, Italy); G. Pinsi (Spedali Civili, Brescia, Italy); R. Caddeu and A.G. Farris (Ospedale Binaghi, Cagliari, Italy); C. Di Naso (Policlinico Ospedaliero Garibaldi Centro, Catania, Italy); P. Cavalcanti (Ospedale Annunziata, Cosenza, Italy); G. Tomei and G. Martini (Ospedale di Chieti, Chieti, Italy); E. Tortoli and M. T. Simonetti (Azienda Ospedaliero-Universitaria di Careggi, Florence, Italy); A. di Taranto (Ospedale di Foggia, Foggia, Italy); E. Senno (Ospedale S. Martino, Genoa, Italy); S. Nisticò (Ospedale di Lamezia Terme, Catanzaro, Italy); C. Colonna and L. Buono (Ospedale Contrada Ambulante, Matera, Italy); E. Mazzola and G. Gesu (Azienda Ospedaliera Niguarda Ca’ Granda, Milan, Italy); P. Cichero (Ospedale di S. Raffaele, Milan); A. Lombardi (Ospedale di Sacco, Milan); A. Fabio, (Policlinico di Modena, Modena, Italy); G. Santoro (Azienda Ospedaliera dei Colli, Ospedale V. Monaldi, Naples, Italy); G.L. Molinari and A. Camaggi (Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy); M.G. Chirillo (Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Turin, Italy); M. Peracchi and L. Fallico (Azienda Ospedaliero di Padova, Padua, Italy); P. Marone and L. Bonò (IRCCS S. Matteo, Pavia, Italy); R. Mazzolla and C. Ticeo (Azienda Ospedaliero S. Maria della Misericordia, Perugia, Italy); P. Chiaradonna, M. Tronci and A. M. Altieri (Azienda Ospedaliero S. Camillo-Forlanini, Rome, Italy); E. Bordi, P. De Mori and A. Di Caro (INMI, Ospedale S. Scallozzino, Rome); E. Libanori and S. De Lorenzo (Azienda Ospedaliero-Universitaria Valtellina e Valchiavenna, Sondalo, Italy); R. Milano and A. Mondo (Ospedale A. Di Savoia, Turin); A. Barbui (Azienda Ospedaliero-Universitaria S. Giovanni Battista, Turin); R. Centis, L. D’Ambrosio and A. Spanevello (Fondazione S. Maugeri, Tradate, Italy); I. Caola (Ospedale di Trento, Trent, Italy); C. Fabris (Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy); and M.C. Scem and C. Scarpa (Azienda Ospedaliero-Universitaria S. Maria della Misericordia, Udine, Italy).

REFERENCES

DOI: 10.1183/00319366.00021012
Dear Author

During the preparation of your manuscript for publication, the questions listed below have arisen. Please attend to these matters and return this form with your proof. Many thanks for your assistance.

<table>
<thead>
<tr>
<th>Query Reference</th>
<th>Query</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Should there be values for &quot;H and R resistance&quot; or are the subsequent entries in the first column subdivisions of this?</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>I have changed &quot;Romanians&quot; to &quot;Romanian-born persons&quot; as I understood it to mean Romanian FBPs.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>For ref. 3, please provide a specific URL that links directly to the cited data, and the date upon which you last accessed the page and the date upon which it was last updated.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>I have amended ref. 8 to a more precise URL. Please supply dates last accessed and last updated.</td>
<td></td>
</tr>
</tbody>
</table>